Allogeneic bone marrow transplantation (BMT) is becoming the treatment of choice for many patients with hematological malignancies or primary immunodeficiency. [1] [2] [3] However, only 30% of patients have an HLAidentical sibling donor available and, for the rest, matched unrelated donors (MUD) or partially mismatched siblings become alternative sources of hematopoietic stem cells. 4 BMT from these donors is, however, associated with an increased incidence and severity of graft-versus-host disease (GVHD) and graft failure. [5] [6] [7] [8] [9] [10] We have previously shown that helper T-lymphocyte precursor frequencies (HTLP f ) may predict the occurrence of GVHD in transplantation from HLA-identical sibling donors in a Chinese population. 11 We report here an extended study of CTL precursor frequencies (CTLP f ), HTLP f and interferon (IFN)-gproducing cell frequencies (IFN-gP f ) in BMT from both HLA-identical siblings or MUD.
Patients and methods

Patients
In all, 19 patients (17 adults and two children) receiving BMT from MUD and 29 adult patients receiving BMT from HLA-identical sibling donors, between July 1997 and December 2001, were included in this study. Their clinical characteristics are shown in Table 1 . All patients received unmanipulated bone marrow or mobilized peripheral blood (PB) stem cell transplants. HLA-A, -B and -DR were identified by medium-high resolution molecular typing using polymerase chain reaction with sequence-specific primers. The HLA typing of the patients and the unrelated donors are shown in Table 2 .
Post transplantation treatment
Prophylaxis against GVHD comprised methotrexate (15 mg/m 2 on day 1, 10 mg/m 2 on days 3, 6 and 11) and cyclosporin A (3 mg/kg/day intravenously or 9 mg/kg/day orally on days 1-50, tailed off at 6 months). The severity of GVHD was graded as described by Glucksberg et al 12 and was classified into mild (overall grade o2) or severe (overall grade X2). Patients developing GVHD received additional immunosuppression according to the discretion of the attending physicians. This included intravenous methylprednisolone (2 mg/kg/day, increased to 4 mg/kg/day if no response within 48 h), and for patients with refractory GVHD, horse antithymocyte globulin (25 mg/kg/day for 5 days). Patients who received mobilized peripheral blood stem cell transplant. All the other patients received BMT.
HTLPf, IFN-cPf, CTLPf predicts GVHD
Measurement of HTLP f , CTLP f and INF-gP f using limiting dilution analysis Collection and storage of peripheral blood mononuclear cells (PBMNC). PB was collected from donors and recipients before BMT and MNC were separated by density-gradient centrifugation on Lymphoprep (Axis-Shield, Oslo, Norway), resuspended in 5 ml of the tissue culture medium RPMI 1640 containing 10% fetal calf serum (Invitrogen, USA) (FCS-RPMI) and diluted 10-fold with WBC solution. The cell density was determined and adjusted to 2 Â 10 7 cells/ml and the cells were frozen in 1 ml aliquots in liquid nitrogen.
Combined HTLP f , CTLP f and IFN-gP f assays. Cryopreserved PBMNC were thawed and washed, counted and diluted to a concentration of 10 6 cells/ml. Recipient cells were the stimulators and donor cells the responders. HTLP f , CTLP f and INF-gP f were determined in the graftversus-host direction from a single limiting dilution assay (LDA). 13 In brief, a LDA was setup by culturing limiting numbers of responder cells (5 Â Completely mismatched third-party cells were used either as effector or stimulator to determine stimulator capacity of the irradiated stimulator cells or the responsive capacity of the effector cells, respectively. After 3 days, the plates were centrifuged at 200 g for 1 min and 100 ml of each supernatant was transferred onto new plates and frozen at -701C until use in the HTLP f assay. On day 6, the steps were repeated to obtain another 100 ml of each supernatant for IFN-gP f assay. The fresh medium supplemented with human rIL2 (20 U/ml 0.01 mg/ml) (Boehringer Mannheim) was added to the wells of the LDA culture on days 3 and 6. On day 10, CTLP f was determined. HTLP f , IFN-gP f and CTLP f estimations were calculated using the computer program developed by Strijbosch et al. 14 The frequency of the responding cells was determined by the maximumlikelihood estimation using a computer program as described by Fazekas de St Groth. 15 
HTLP f assay
Proliferation of the IL-2-dependent cell line CTLL-2 was used as the readout for the detection of IL-2 secretion by alloreactive T cells. This cell line was maintained in RPMI 1640 in the presence of L-glutamate (2 mmol/ml), pyruvate (100 U/ml), penicillin and streptomycin (100 mg/ml) (Gibco, USA), FCS (10%) (Invitrogen, USA) and human rIL2 (20 U/ml) (Boehringer Mannheim) at 371C in a humidified atmosphere containing 5% CO 2 . Before use, the CTLL-2 cells were washed three times with phosphate-buffered saline and then resuspended in the culture medium without IL-2.
The HTLP f assay was performed as described previously, 16 with some modifications. Briefly, frozen plates containing supernatant as described above were thawed, and 1 Â 10 3 CTLL-2 cells in 50 ml culture medium were added to each well. After 48 h of incubation at 371C, 0.5 mCi [ 3 H]TdR was added to each well and the plates were harvested the following day and counted. A dose-response curve was setup to determine the cutoff point for scoring positive and negative wells in the HTLP f assay. The cutoff value for the assay was set at the beginning of the linear part of the dose-response curve. HTLP f were determined from the proportion of wells negative for IL-2 production at each responder (donor) cell dilution. Wells were scored positive for IL-2 production if the [ CTLP f assay. The target cells were generated from the original stimulator or third-party PBMC by incubating the cells (10 6 /ml) with purified PHA-P (Difco, 5 mg/ml) from days 0 to 6, and with IL-2 (20 U/ml) from days 3 to 10. On day 8, target cells were incubated at 371C in a humidified atmosphere containing 5% CO 2 for 48 h in the presence of 10 mCi [ /l 28 days after transplantation. Secondary graft failure was defined as the disappearance of myeloid engraftment in patients in whom neutrophils had previously engrafted. Development of acute graft-versus-host disease (aGVHD) was established by the standard criteria. 17 Patients who died within 28 days of BMT or patients with primary graft failure were not evaluated for aGVHD.
Statistical analysis.
Comparisons between groups of data were performed using the w 2 test (categoric data). The probability of aGVHD was calculated by the KaplanMeier method. 18 P-values less than 0.05 were considered statistically significant.
RESULTS
Baseline characteristics
The clinical characteristics of patients are shown in Table 1 . Their median age was 35 years (range: 4-57). The median duration of follow-up was 8 months (range: 2-26). The median time of neutrophil engraftment for all patients was 22 days (range: 15-28 days). Two patients were excluded from analysis because they died of transplant-related toxicity.
Correlation between HTLP f , CTLP f and IFN-gP f and clinical outcomes (Tables 3a-d) When using an arbitrary cutoff of 5 Â 10
À6
, HTLP f was significantly associated with the severity of aGVHD in patients who received BMT from HLA-identical sibling donors and MUD, both when they were separately analyzed or grouped together (Table 3a) . The same results were obtained when CTLP f was assayed (Table 3b) . IFNgP f , however, was significantly associated with aGVHD when BMT from matched sibling donors was considered (Table 3c ). When only BMT from MUD was analyzed, no significant association between IFN-gP f and aGVHD could be demonstrated. We further investigated whether the combination of these parameters can better identify patients who are at risk of aGVHD (Table 3d ). In all patients studied (either HLA-identical siblings or MUD analyzed separately or together), a low frequency (p5 Â 10
) of all three parameters was associated with a low risk of aGVHD. On the other hand, a high frequency (45 Â 10 À6 ) of all three parameters was distinctly associated with a high risk of aGVHD.
In this cohort of 48 patients, only five patients had disease relapse post-BMT and the risk was not significantly associated with HTLP f , CTLP f or IFN-gP f . These parameters were not associated with neutrophil engraftment in our patients.
Discussion
We have evaluated alloimmune reactive donor CTLP f , HTLP f and IFN-gP f using a LDA in 19 patients who received BMT from MUD and 29 patients who received BMT from HLA-identical siblings. In both groups of patients, we demonstrated a significant association between CTLP f and HTLP f and the occurrence of aGVHD. IFN-gP f was also associated with aGVHD in patients receiving BMT from HLA-identical siblings, but not in those receiving BMT from MUD. Similar results have been reported by others [19] [20] [21] [22] [23] [24] [25] [26] and our group, 27 and the present study demonstrated some interesting findings that might be of clinical importance. First, although HTLP f /CTLP f were associated with aGVHD in general, some patients with high HTLP f /CTLP f did not develop severe aGVHD, whereas others who develop aGVHD had low HTLP f /CTLP f levels. It could be that some minor histocompatibility antigens are expressed in a tissue-specific manner, and those expressed by peripheral blood mononuclear cells may be different from those expressed by the target tissues for GVHD. Along the same argument, those antigens that present at higher frequencies on stimulator PBMCs may indicate a graft-versus-hematopoietic cell or graft-versus-leukemia reaction, rather than a GVHD reaction. Another explanation for 'unexpectedly' high HTLP f in some patients is related to the polymorphic proteins derived from the fetal calf or human AB sera used for cryopreservation of cells or in the assay culture medium. Some foreign serum proteins may be processed and on occasion presented in vitro as antigenic peptides. [28] [29] [30] [31] IFN-g production has been reported to be sensitive to HLA class II differences, 32 but this finding was not confirmed in this study. Not all donors and recipients in the present study were tested at the allelic level for HLA-DRB1. Moreover, HLA-DQ and HLA-DP matching was not taken into consideration in this study. Whether allelic differences at these loci played any part in the observed results remains to be seen. The ethnic background in this Chinese patient-donor cohort also needs to be considered as genetic differences in reactivity related to racial origin may also play a role. We also demonstrated that using a combination of CTLP f /HTLP f /IFN-gP f assay may better predict the occurrence of aGVHD in both sibling and MUD. The clinical significance of this finding would have to be further studied with a larger cohort of patients.
In conclusion, CTLP f and HTLP f are significantly associated with aGVHD in Chinese patients receiving BMT from HLA-identical siblings and MUD, while IFN-gP f is significantly associated with aGVHD in patients receiving BMT from HLA-identical siblings. A larger cohort of patients is needed to investigate the predictive role of CTLP f , HTLP f and IFN-gP f in aGVHD and disease relapse.
